All right, Ms. Kramer. On your website you explain that your organization works with a number of organizations in the United States, the Infectious Diseases Society of America, the American Medical Association and such, to promote U.S. public policy and legislation that will maintain incentives for pharmaceutical antibiotic development and appropriate use.
Can you describe some of the existing incentives that are out there right now for pharmaceutical antibiotic development and appropriate use in the United States?